{
  "abstract": "Background: Antibody–drug conjugates (ADCs) have emerged as potential treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) resistance. We evaluated their efficacy and safety in this setting.\n\nMethods: PubMed, Embase,and the Cochrane Library were searched for prospective clinical studies. Overlapping reports were assessed before endpoint-specific synthesis. Comparable proportional outcomes from non-randomized studies were pooled using random-effects models, whereas randomized controlled trials (RCTs) were summarized separately.\n\nResults: Eight eligible clinical study reports were included. Four non-randomized reports contributed five independent underlying trial datasets; however, the ORR and DCR meta-analysis each included four non-overlapping analytical estimates because one pooled Dato-DXd estimate represented two underlying trial datasets that were not entered separately. The pooled ORR was 39.2%(95% CI,31.1%–48.0%),and the pooled DCR was 78.9%(95% CI,72.3%–84.2%).Three comparable non-overlapping datasets contributed to the grade ≥3 TEAE analysis, yielding a pooled incidence of 65.2%(95% CI,50.2%–77.7%),whereas four analytical datasets contributed to the ILD analysis, with a pooled reported incidence of 6.0%(95% CI,4.1%–8.5%).Two RCTs provided comparative evidence supporting sac-TMT, particularly for ORR and PFS.\n\nConclusions: ADCs showed antitumor activity after EGFR-TKI resistance, but efficacy and toxicity varied across platforms. Additional randomized trials and biomarker-informed studies are needed to define the optimal use of individual ADCs.\n\nSystematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261288638 , identifier CRD420261288638.",
  "abstract_shown": true,
  "affiliations": [
    "Zhejiang Chinese Medical University",
    "First Hospital of Jiaxing, Jiaxing"
  ],
  "article_type": "systematic review",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yilin Chen"
    },
    {
      "affs": [
        0
      ],
      "name": "Shuaixuan Chen"
    },
    {
      "affs": [
        0
      ],
      "name": "Hang Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "Jiebo Xie"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Binbin Song"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Yufen Xu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2eha6xf5vwvdw.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1909040",
  "fulltext_url": "https://europepmc.org/articles/PMC13713261",
  "id": "2eha6xf5vwvdw",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1909040/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Systematic Review"
    ],
    [
      "openalex",
      "2740|Lung Cancer Treatments and Mutations"
    ]
  ],
  "openalex": "W7221793242",
  "pdf_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1909040/pdf",
  "pmcid": "PMC13713261",
  "pmid": "42952490",
  "published": "2026-10-14",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/2eha6xf5vwvdw.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1909040",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1909040/full"
    },
    {
      "first_seen": "2026-10-31T00:20:34Z",
      "native_id": "MED:42952490",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42952490"
    },
    {
      "first_seen": "2026-10-31T12:23:50Z",
      "native_id": "PMC13713261",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fonc.2026.1909040"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "Efficacy and safety of antibody–drug conjugates in EGFR-mutated non-small cell lung cancer after EGFR-TKI resistance: a systematic review and meta-analysis",
  "title_text": "Efficacy and safety of antibody–drug conjugates in EGFR-mutated non-small cell lung cancer after EGFR-TKI resistance: a systematic review and meta-analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-11-01T12:20:57Z",
  "url": "https://research.draconitic.com/paper/2eha6xf5vwvdw",
  "venue": "Frontiers in Oncology",
  "versions": []
}